Skip to the page

Data / Form D filings / Ancilia Biosciences, Inc.

Ancilia Biosciences, Inc.: Form D filings

Ancilia Biosciences, Inc., a company in New York, NY, filed 2 Form D notices with the SEC between 2023 and 2026. The latest, on April 6, 2026, reports $10.1 million sold of a $10.1 million offering to 23 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
3960 BROADWAY, 6TH FLOOR, New York, NY, 10032
Phone
(716) 474-6710
Industry
Other
Entity type
Corporation
Incorporated in
Delaware
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1975776

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Apr 6, 2026New notice$10,076,464$10,076,46423Feb 13, 2026sec.gov
May 4, 2023New notice$5,000,000$1,000,000$4,000,0002Apr 13, 2023sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
ALEXANDRA SAKATOSExecutive Officer, Director
RODOLPHE BARRANGOUExecutive Officer, Director
DALE PFOSTDirector
VERA SCHROEDERDirector
GURDANE BHUTANIDirector

Other companies in New York that filed recently

Every Form D from the week of Apr 6, 2026 · All recent filings in New York · All recent Other filings

Read from SEC EDGAR. Amount sold is what Ancilia Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.